Literature DB >> 17136979

The challenges of chronic obstructive pulmonary diseases (COPD)--a perspective.

R William Vandivier1, Norbert F Voelkel.   

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disease, primarily caused by cigarette smoke, which will soon become the third leading cause of death globally. Despite the importance of the problem, our real understanding of the biological underpinnings of COPD remains incomplete. Consequently, our first-line therapies, while helpful, are not yet as effective as they need to be. In this review, we will focus on these challenges and more, including the role of impaired tissue repair and adaptive immunity in disease pathogenesis, determining who may be at risk, describing COPD phenotypes and potential biomarkers. New ideas for chronic disease management and prevention of exacerbations will also be discussed. While much remains to be accomplished, meeting these challenges will bring rewards because what we learn will have implications for the understanding and treatment of chronic inflammatory diseases beyond COPD.

Entities:  

Mesh:

Year:  2005        PMID: 17136979     DOI: 10.1081/copd-200050676

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  3 in total

Review 1.  Angiogenesis in chronic lung disease.

Authors:  Norbert F Voelkel; Ivor S Douglas; Mark Nicolls
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

2.  Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S' subsite binding.

Authors:  Yi Li; Dengfeng Dou; Guijia He; Gerald H Lushington; William C Groutas
Journal:  Bioorg Med Chem       Date:  2009-04-12       Impact factor: 3.641

3.  Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA.

Authors:  Tiffany R Richens; Derek J Linderman; Sarah A Horstmann; Cherie Lambert; Yi-Qun Xiao; Robert L Keith; Darren M Boé; Konosuke Morimoto; Russell P Bowler; Brian J Day; William J Janssen; Peter M Henson; R William Vandivier
Journal:  Am J Respir Crit Care Med       Date:  2009-03-05       Impact factor: 21.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.